S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
NASDAQ:PRTC

PureTech Health (PRTC) Stock Price, News & Analysis

$26.15
-0.78 (-2.90%)
(As of 04/19/2024 08:51 PM ET)
Today's Range
$26.15
$26.15
50-Day Range
$22.05
$30.91
52-Week Range
$17.08
$34.00
Volume
100 shs
Average Volume
4,238 shs
Market Capitalization
$706.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

PureTech Health MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.53mentions of PureTech Health in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.67) to ($3.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.14 out of 5 stars

Medical Sector

889th out of 908 stocks

Pharmaceutical Preparations Industry

413th out of 421 stocks

PRTC stock logo

About PureTech Health Stock (NASDAQ:PRTC)

PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

PRTC Stock Price History

PRTC Stock News Headlines

PureTech Health (NASDAQ:PRTC) Shares Gap Down to $26.94
PureTech Health: Notice of Results
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
PureTech Health (NASDAQ:PRTC) Shares Gap Down to $27.93
PureTech Health (NASDAQ:PRTC) Sees Large Volume Increase
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
AKLI Mar 2024 3.000 call
PureTech to Present at Two Upcoming Investor Conferences
PureTech to Present at Two Upcoming Investor Conferences
PureTech Health plc (PRTC)
LSE:PRTC (PureTech Health plc)
PRTC PureTech Health plc
PureTech outlook for 2024
See More Headlines
Receive PRTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/21/2024
Next Earnings (Estimated)
4/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRTC
Employees
111
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$15.62 million
Book Value
$19.64 per share

Miscellaneous

Free Float
25,564,000
Market Cap
$706.05 million
Optionable
Not Optionable
Beta
1.23
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Spencer Ball
    Senior Vice President of Human Resources
  • Ms. Aleksandra Filipovic M.D.
    Ph.D., Head of Oncology
  • Ms. Cheryl Murphy Ph.D.
    Head of Grants Management & Strategy
  • Ms. Anita Terpstra J.D.
    Ph.D., Senior VP & Head of Intellectual Property
  • Mr. Dilip Kodira
    Head of Data Science
  • Ms. Anne Burkhardt Ph.D.
    Head of Research
  • Dr. Julie Krop M.D. (Age 58)
    Chief Medical Officer
  • Ms. Joy Bauer M.S.
    RDN, Chief Nutrition Officer
  • Mr. Robert Lyne (Age 41)
    Chief Portfolio Officer
  • Mr. William Berry CPA
    Controller

PRTC Stock Analysis - Frequently Asked Questions

How have PRTC shares performed in 2024?

PureTech Health's stock was trading at $28.18 at the beginning of the year. Since then, PRTC stock has decreased by 7.2% and is now trading at $26.15.
View the best growth stocks for 2024 here
.

When is PureTech Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024.
View our PRTC earnings forecast
.

How do I buy shares of PureTech Health?

Shares of PRTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRTC) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners